中性粒子の特異的なSTAT3標的化は,細胞毒性CD8+T細胞の拡大によって腫瘍の進行を阻害する
Irem Ozel1, Guanyu Sha1, Agnieszka Będzińska2
1Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Essen, Essen, University of Duisburg-Essen, Essen, 45147, Germany.
Signal transduction and targeted therapy
|August 30, 2025
まとめ
中性粒子のSTAT3信号をターゲットにすることで,腫瘍の成長と転移を抑制します. このアプローチは細胞毒性CD8+T細胞の活性を増強し,がんの免疫療法における有望な新しい道を示しています.
科学分野:
- 腫瘍学
- 免疫学
- 分子生物学
背景:
- 中性粒子は腫瘍の進行と 癌の予後不良に関与しています
- ガンにおける中性粒子の機能を標的とする現在の戦略は,限られた治療効果を示している.
研究 の 目的:
- 中性粒子のシグナルトランスデューサーとトランスクリプションアクティベーター3 (STAT3) のシグナル伝達を,がん治療戦略としてブロックする可能性を調査する.
- 中性粒子の特異的なSTAT3抑制が腫瘍の成長,転移,および抗腫瘍免疫反応に与える影響を評価する.
主な方法:
- 腫瘍の成長と転移を評価するために,中性粒子の特異的なStat3条件付きノックアウトマウス (Ly6GcreStat3fl/ fl) を使用した.
- MHCII,CD80/86,ICAM-1表現を含む中性粒子のフェノタイプを分析した.
- CD8+ T細胞活動に焦点を当てた腫瘍と腫瘍排水リンパ節の免疫細胞群を検査した.
- 小分子阻害剤LLL12とSTAT3反意味オリゴヌクレオチド (CpG- STAT3ASO) をそれぞれ患者由来腫瘍エクスプラントとインビボマウスモデルで使用した.
主要な成果:
- 中性粒子の特異的なStat3消去は,マウスの腫瘍の成長と転移を著しく阻害した.
- ノックアウトされたマウスの中性粒子は,重要な免疫マーカーの発現が増加した抗腫瘍フェノタイプを示した.
- 腫瘍とリンパ節は,高度に細胞毒性のあるCD8+T細胞 (granzymeBhi, perforinhi,IFN-γhi) の濃縮を示した.
- 人間の中性粒子のSTAT3抑制と in vivo マウスモデルでは,細胞毒性CD8+T細胞の活性が強化され,腫瘍の負荷が軽減されました.
結論:
- 中性粒子のSTAT3シグナル伝達は前立腺活動を促進し,がんの進行に寄与する.
- 中性粒子のSTAT3シグナリングをターゲットにすることは,がんの免疫療法における有望な戦略です.
- このアプローチは,抗腫瘍免疫,特に細胞毒性T細胞の反応を強化し,新たな治療法を提供します.
関連する概念動画
mTOR Signaling and Cancer Progression
3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.9K
Cytotoxic T Cells-mediated Immune Response
1.9K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
1.9K
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
The Tumor Microenvironment
6.8K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.8K
Tumor Immunotherapy
659
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
659
The JAK-STAT Signaling Pathway
9.2K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
9.2K


